NCT03712787
Brief summary
The purpose of this study is to assess the long-term safety and tolerability of an active drug in subjects with early AD.
Interventional study
- 1
- 2
- 3
- 4
Would you like to know more about this trial?
|
Please note, participation in the clinical trial is open to patients with the disease or condition under investigation. |
Age:
From 57 Years to 88 Years.
Inclusion Criteria:
- All subjects with early AD who complete Study M15-566 (NCT02880956), meet all
inclusion criteria, and do not meet any exclusion criteria are eligible for enrollment
- Subject was compliant during participation in Study M15-566 (NCT02880956)
- Subject has an identified, reliable study partner who has frequent contact with the
subject and who will provide information as to the subject's cognitive and functional
abilities
Exclusion Criteria:
- The subject has any significant change in his/her medical condition since
participation in Study M15-566 (NCT02880956) that could interfere with the subject's
participation in Study M15-570, could place the subject at increased risk, or could
confound interpretation of study results
- More than 8 weeks have elapsed since the subject received his/her last dose of study
drug in Study M15-566 (NCT02880956)
- The subject is concurrently enrolled in another interventional clinical study
involving a therapeutic agent with the exception of Study M15-566 (NCT02880956)
